205194-12-3

Basic information

• Product Name: (R)-Ethyl 1-methylpiperidine-3-carboxylate
• Synonyms: (R)-Ethyl 1-methylpiperidine-3-carboxylate;3-Piperidinecarboxylic acid, 1-methyl-, ethyl ester, (3R)-;(R)-ethyl 1-methylpiperdine-3-carboxylate;VFJJNMLPRDRTCO-MRVPVSSYSA-N
• CAS NO: 205194-12-3
• Molecular Formula: C9H17NO2
• Molecular Weight: 171.24
• Product Categories: API intermediates
• Mol File: 205194-12-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 211.1°C at 760 mmHg
• Flash Point: 68.3°C
• Appearance: /
• Density: 0.997g/cm³
• Vapor Pressure: 0.186mmHg at 25°C
• Refractive Index: 1.458
• CAS DataBase Reference: (R)-Ethyl 1-methylpiperidine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-Ethyl 1-methylpiperidine-3-carboxylate(205194-12-3)
• EPA Substance Registry System: (R)-Ethyl 1-methylpiperidine-3-carboxylate(205194-12-3)

Safety Data

• Hazardous Substances Data: 205194-12-3(Hazardous Substances Data)

Usage

General Description

(R)-Ethyl 1-methylpiperidine-3-carboxylate is a chemical compound with the molecular formula C10H19NO2. It is a derivative of piperidine, a six-membered heterocyclic ring commonly found in many pharmaceutical and organic compounds. (R)-Ethyl 1-methylpiperidine-3-carboxylate is primarily used in the synthesis of various pharmaceutical drugs, including antipsychotics and analgesics. It is also used as a chiral building block in organic chemistry for the production of enantiomerically pure compounds. The (R) configuration in its name indicates that the molecule has a specific stereochemistry, meaning that it has a chiral asymmetry, which is important for its biological activity and interactions with other molecules. Overall, (R)-Ethyl 1-methylpiperidine-3-carboxylate is a valuable compound in the pharmaceutical and chemical industries, playing a crucial role in the synthesis of drugs and other organic compounds.

InChI:InChI=1/C9H17NO2/c1-3-12-9(11)8-5-4-6-10(2)7-8/h8H,3-7H2,1-2H3/t8-/m1/s1

Upstream product

• 64-18-6 formic acid 
• 25137-01-3 (R)-ethyl nipecotate 
• 50-00-0 formaldehyd 

Downstream Products

• 952480-19-2 (R)-1-methylpiperidine-3-carboxylic acid 
• 205194-11-2 (R)-3-hydroxymethyl-1-methylpiperidine 

Relevant articles and documents

Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants

A novel class of HIV-1 protease inhibitors with flexible piperidine as the P2 ligand was designed with the aim of improving extensive interactions with the active subsites. Many inhibitors exhibited good to excellent inhibitory effect on enzymatic activity and viral infectivity. In particular, inhibitor 3a with (R)-piperidine-3-carboxamide as the P2 ligand and 4-methoxybenzenesulfonamide as the P2’ ligand showed an enzyme Ki value of 29 pM and antiviral IC50 value of 0.13 nM, more than six-fold enhancement of activity compared to DRV. Furthermore, there was no significant change in potency against DRV-resistant mutations and HIV-1NL4?3 variant for 3a. Besides, inhibitor 3a exhibited potent antiviral activity against subtype C variants with low nanomole EC50 values. In addition, the molecular modeling revealed important hydrogen bonds and other favorable van der Waals interactions with the backbone atoms of the protease and provided insight for designing and optimizing more potent HIV-1 protease inhibitors.

QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS

The invention relates to the use of compounds of the formula I: wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NRR (wherein R and R, which may be the same or different, each represents hydrogen or C1-3alkyl), or RX- (wherein X and R are as defined herein; R represents hydrogen, oxo, halogeno, hydroxy, C1-4alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group RX (wherein X and R are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.